September 17, 2013Open Access

Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

Bromodomain inhibition comprises a promising therapeutic strategy for KRAS-mutant NSCLC with wild-type LKB1, via inhibition of MYC function. Clinical studies of BET bromodomain inhibitors in aggressive NSCLC will be actively pursued. Clin Cancer Res; 19(22); 6183-92. ©2013 AACR.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Takeshi Shimamura

Zhao Chen

Margaret Soucheray

Journals

Clinical Cancer Research

Actions

Institutions

Harvard University

Brigham and Women's Hospital

Dana-Farber Cancer Institute

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study